3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Fallopian Tube Neoplasms
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Oxaliplatin
19
pembrolizumab
13
Fluorouracil
12
Leucovorin
11
Capecitabine
11
Paclitaxel
10
Gemcitabine
9
Docetaxel
8
zolbetuximab
6
cemiplimab
6
Cisplatin
6
Albumin-Bound Paclitaxel
6
durvalumab
5
Ramucirumab
5
Radiotherapy
5
130-nm albumin-bound paclitaxel
5
Irinotecan
4
Cyclophosphamide
4
trastuzumab deruxtecan
3
tislelizumab
3
lenvatinib
3
enzalutamide
3
darolutamide
3
Trastuzumab
3
Taxes
3
S 1 (combination)
3
Radiosurgery
3
Pemetrexed
3
Nivolumab
3
Carboplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
Poly(ADP-ribose) Polymerase Inhibitors
×
1 year
×
Clear all
NCT07268794
2025-12-08
CONVERT-HB1
Fudan University
Phase 2
Not yet recruiting
112 enrolled